LARS Inhibition Overcomes Regorafenib Resistance in Hepatocellular Carcinoma via Ferroptosis and Drug Metabolism.
BACKGROUND Regorafenib improves outcomes in advanced hepatocellular carcinoma (HCC), but acquired resistance limits its durable therapeutic benefit. The metabolic and redox mechanisms driving regorafenib resistance remain incompletely defined. METHODS Regorafenib-resistant Huh7 and Hep3B cell (RegR-) models were gene...